Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IB/II Study Combining All-Trans Retinoic Acid (ATRA) With Carfilzomib Based Therapy in Plasma Cell Myeloma Patients Refractory to Carfilzomib

NCT06536413 is registered in ClinicalTrials.gov with The Methodist Hospital Research Institute as lead sponsor.

NCT NCT06536413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06536413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IB/II Study Combining All-Trans Retinoic Acid (ATRA) With Carfilzomib Based Therapy in Plasma Cell Myeloma Patients Refractory to Carfilzomib
Lead sponsor
The Methodist Hospital Research Institute
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 29, 2024
Completion date
July 31, 2030
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma